BiotechTube

Pemigatinib

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation

Trial Timeline

Nov 11, 2022 → Mar 27, 2025

NCT ID
NCT05565794

About Pemigatinib

Pemigatinib is a phase 2 stage product being developed by Incyte for Intrahepatic Cholangiocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05565794. Target conditions include Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement.

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholangiocarcinoma were approved

Approved (0) Terminated (1) Active (3)
🔄A4250 (odevixibat)IpsenPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (15)

NCT IDPhaseStatus
NCT03906357Pre-clinicalCompleted
NCT07434843Phase 2Recruiting
NCT06300528Phase 2Recruiting
NCT06906562Phase 2Recruiting
NCT06653777Phase 2Recruiting
NCT05565794Phase 2Terminated
NCT05267106Phase 2Terminated
NCT05253807Phase 2Completed
NCT03914794Phase 2Completed
NCT04294277Phase 2Terminated
NCT04003623Phase 2Terminated
NCT03822117Phase 2Terminated
NCT03235570Phase 1Completed
NCT03011372Phase 2Completed
NCT02924376Phase 2Completed

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
31
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
42
ApatinibJiangsu Hengrui MedicinePhase 2
35
FamitinibJiangsu Hengrui MedicinePhase 2
27
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
31
Durvalumab + SNDX-6352AstraZenecaPhase 2
35
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Pemigatinib + DurvalumabAstraZenecaPhase 2
42
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
42
A4250 (odevixibat)IpsenPhase 3
37
OdevixibatIpsenPre-clinical
23
CGT4859Cogent BiosciencesPhase 1/2
36
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
32
MaralixibatMirum PharmaceuticalsPhase 3
37
MaralixibatMirum PharmaceuticalsPhase 2
39
MaralixibatMirum PharmaceuticalsPhase 2
32
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
24
MaralixibatMirum PharmaceuticalsPhase 3
37
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
29
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
23